GeneGrafts

Company Overview

Snapshot

Founded in November 2003, GeneGrafts operates with 1–10 employees. The company has raised $800,000 across one funding round from one investor. In November 2018, GeneGrafts ceased to operate.

Business overview

GeneGrafts Ltd is a biotechnology company focused on developing proprietary cell therapy technology to modulate excitable tissues, such as those found in the brain or heart. Its core technology platform involves transplanting cell grafts, isolated from the patient's own body, which define ion channels. These grafted cells functionally and structurally integrate with the target organ, allowing their electrical properties to be derived from the expressed ion channels, thereby modulating the electrical properties of the target organ in a predetermined manner. This approach is designed for the treatment of various diseases, including Parkinson's disease and other neurological disorders, as well as cardiac arrhythmias, operating within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is GeneGrafts' primary focus?

GeneGrafts is a biotechnology company developing proprietary cell therapy technology for modulating excitable tissues, such as the brain or heart.

When was GeneGrafts founded?

GeneGrafts was founded in November 2003.

What is the core technology behind GeneGrafts' approach?

The company's technology platform is based on transplanting cell grafts, isolated from the patient's own body, which define ion channels to functionally integrate with target organs and modulate their electrical properties.

What medical conditions does GeneGrafts' technology aim to address?

GeneGrafts' technology is intended for the treatment of various diseases, including Parkinson's disease, other neurological disorders, and cardiac arrhythmias.

What is the current operational status of GeneGrafts?

GeneGrafts ceased to operate in November 2018.